Biotech-beleggers opgelet, nee we hebben het niet over Pharming, maar over Amgen. Het grootste Biotechbedrijf van de wereld qua omzet staat +3,5% hoger in de pre-markit. Het bedrijf is bezig met een nieuw medicijn genaamd Kyprolis. FT schrijft:
Kyprolis, the drug at the centre of the trial, increased the time patients lived without their disease worsening by 8.7 months compared to those treated without it. Amgen said the results would help form the basis of the drug's submission for regulatory approval in the first half of 2015. Wall Street analysts have set high expectations for the drug, with those at UBS expecting sales to reach $1.2bn by 2016.
Robert Bradway, chief executive of Amgen, hailed the trial's results, adding: Coupled with our recent U.S. regulatory submissions for ivabradine and talimogene laherparepvec and our upcoming regulatory submissions for evolocumab and blinatumomab, our pipeline continues to show notable progress.
Een ander Biotechbedrijf met de naam Tekmira Pharmaceuticals gaat ook als een speer. Vrijdag +11% en nu in de pre-markit +9,5%, dat gaat hard. Nu wilt u vast weten waarom. Nou, het bedrijf is bezig met een medicijn tegen het Ebola virus. Van BusinessInsider:
In its report, Reuters noted that the FDA's hold means Tekmira can't proceed with the trial placed on hold, but doesn't prevent the company from initiating a new study proposal.
And were the company to initiate a new trial in people already infected with Ebola, "the benefit-risk ratio changes completely," an FDA source told Reuters. "Anything that would shift the risk-benefit to a more favorable outcome could potentially allow the authorization of that study," the source told Reuters.
Tekmira's treatment, TKM-Ebola, is currently being developed under a $140 million contract with the Department of Defense's Medical Countermeasure Systems BioDefense Therapeutics Joint Product Management Office.